90 search results for screening
Webinars for Patients
Neoplasms (MPN) (2024) Breast Cancer Screening (2024) Advanced and Metastatic Bladder Cancer (2024
https://www.nccn.org/patientresources/patient-resources/patient-webinarsDecember 2022 Summit Report
Purpose of the Summit Patients with cancer often have widely divergent care experiences from screening through survivorship. Differences in care delivery and outcomes may be due, in part, to varying patient preferences, patient needs according to varying intersectional identities, barriers to accessing appropriate and affirming cancer screening and treatment. A landscape, Continuum from Screening through Survivorship Tuesday, December 5, 2023 For More Information: https
https://www.nccn.org/docs/default-source/oncology-policy-program/december-2022-summit-report.pdf?sfvrsn=94daf5e7_12023 Summit Report
Patient Advocacy Summit Navigating the Care Continuum from Screening through Survivorship Summary Report Tuesday, December 5, 2023 8:30 AM – 3:30 PM Presented at The National Press Club in Washington, DC and Virtually © 2024 National Comprehensive Cancer Network, Inc. All rights, to thoughtfully discuss issues associated with care transitions, including from screening to diagnosis, Appendix 1. NCCN Patient Advocacy Summit: Navigating the Care Continuum from Screening through
https://www.nccn.org/docs/default-source/oncology-policy-program/2023-summit-report.pdf?sfvrsn=9db11db7_2NCCN-2025-Annual-Conference-Exhibit-Guide
Cancer • Breast Cancer: Metastatic Breast Cancer • Breast Cancer Screening and Diagnosis • Cervical, Cancer Screening • Cutaneous B-Cell Lymphomas • Cutaneous T- C e l l L y m p h o m a s • D i f f u s, Inhibitors • Kidney Cancer • Liver Cancer • Lung Cancer Screening • Mantle Cell Lymphoma • Marginal
https://www.nccn.org/docs/default-source/education-research/nccn-2025-annual-conference-exhibit-guide.pdf?sfvrsn=5765e4e8_5Imaging AUC Compendium
include: Indications Screening Diagnosis Purpose Frequency Staging Treatment response assessment
https://www.nccn.org/compendia-templates/compendia/imaging-appropriate-use-criteria-nccn-imaging-aucBiomarkers Compendium Reviewer Acknowledgment
Memorial Sloan Kettering Cancer Center Colorectal Cancer Screening
https://www.nccn.org/compendia-templates/compendia/biomarkers-compendium/biomarkers-compendium-reviewer-acknowledgmentHIT
Wilms Tumor (Nephroblastoma) Breast Cancer Risk Reduction Breast Cancer Screening and Diagnosis Colorectal Cancer Screening Genetic/Familial High-Risk Assessment: Breast, , and Gastric Lung Cancer Screening Prostate Cancer Early Detection Adult Cancer Pain, - Invasive Breast Cancer Breast Cancer - Metastatic Breast Cancer Breast Cancer Screening, Cancer Screening Cutaneous B-Cell Lymphomas Cutaneous T-Cell Lymphomas Diffuse Large B-Cell
https://www.nccn.org/redirects/hitSubmission Request Form
Cancer - 3.2025 Breast Cancer Risk Reduction - 2.2025 Breast Cancer Screening and Diagnosis - 2.2025, Myeloid Leukemia - 3.2025 Colon Cancer - 2.2025 Colorectal Cancer Screening - 1.2024, - 2.2025 Kidney Cancer - 3.2025 Lung Cancer Screening - 1.2025 Management of Immunotherapy-Related
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formTreatment by Cancer Type
Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening Version: 2024, Cancers Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/treatment-by-cancer-typeDetection, Prevention, and Risk Reduction
Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening Version: 2024, Cancers Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/detection-prevention-and-risk-reductionSupportive Care
Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening Version: 2024, Cancers Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/supportive-careSpecific Populations
Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening Version: 2024, Cancers Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/specific-populationsHarmonized Guidelines
Breast Cancer Screening and Diagnosis Version 2.2024 Colorectal Cancer Screening
https://www.nccn.org/global/what-we-do/harmonized-guidelinesAt a Glance
for the treatment of nearly every type of cancer, as well as key cancer screening and prevention topics, Imaging AUC™) include recommendations pertaining to cancer screening, diagnosis, staging, treatment
https://www.nccn.org/home/news/at-a-glance2021-State-Oncology-Society-Forum-Summary
Screening, Treatment, and Survivorship Laura Makaroff, DO, Senior Vice President, Prevention & Early, and subsequent public awareness campaign that endorsed the safe resumption of cancer screening and treatment, -related delays in cancer screening and treatment. Dr. Richardson discussed the CDC’s COVID-19 Home
https://www.nccn.org/docs/default-source/business-policy/2021-state-oncology-society-forum-summary.pdf?sfvrsn=1a14acee_2(Reconciliation) NCCN Holds Twelfth Annual State Oncology Society Forum 2023
to biomarker testing and screening, as well as various levels of prior-authorization reform, and fertility, Carolina, Oklahoma). Cori Chandler of ACS CAN focused on the importance of biomarker screening and testing
https://www.nccn.org/docs/default-source/oncology-policy-program/(reconciliation)-nccn-holds-twelfth-annual-state-oncology-society-forum-2023.pdf?sfvrsn=4d6f3dd0_1NCCN_Oncology_Research_Program_Brochure
research collaborations between NCCN Member Institutions and industry in cancer screening, of the first lung cancer screening program in Antelope Valley. This initiative has touched many
https://www.nccn.org/docs/default-source/oncology-research-program-(orp)/nccn_oncology_research_program_brochure.pdf?sfvrsn=ebab0181_3NCCN LGBTQ Health Equity Infographic
Asking patients about their preferences for treatment, pronouns, support system, etc. Asking patients about their fertility plans/wishes so they can be fully informed about treatment options available to them. Ensuring educational materials feature diverse representation. Receiving trauma-informed training for this specific population to reduce the likelihood of unintentionally retraumatizing patients during screening, examinations, etc. Providers Need to Create More Welcoming
https://www.nccn.org/docs/default-source/oncology-policy-program/nccn-lgbtq-health-equity-infographic.pdf?sfvrsn=c771d22d_1CEO_Annual_Report_2024_to_BoD_March_2025
cancer specific • 12 supportive care • 7 prevention, screening, risk reduction • 3 specific, cancer specific • 2 pediatric cancer specific • 12 supportive care • 4 prevention, screening, , screening, risk reduction 47,000 237,883 (increased from 228,307 in 2023) Harmonized Guidelines, supportive care • 3 screening • 2 specific populations 5,208 14,891 (decreased from 17,867 in 2023, screening areas, and 2 covering special populations. The guidelines have been endorsed by Federal
https://www.nccn.org/docs/default-source/member-institution/ceo_annual_report_2024_to_bod_march_2025.pdf?sfvrsn=a284d492_1HERC Healthcare Abbreviated
• Offer Flexible Hours for Screening and Treatment • Offer Representative Patient Navigators
https://www.nccn.org/docs/default-source/oncology-policy-program/herc-healthcare-abbreviated.pdf?sfvrsn=fa3b6f46_1